LIVE WEBINAR: Thursday, April 29, 2021, 5:00 PM – 6:30 PM Eastern Time

Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers

13th Annual Oncology Grand Rounds NCPD Webinar Series

Chimeric Antigen Receptor T-Cell Therapy

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Thursday, April 29th for this NCPD-accredited webinar
5:00 PM – 6:30 PM ET

Faculty
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Caron Jacobson, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Nurse Case Presentations By
Sonia Glennie, ARNP, MSN, OCN
Swedish Cancer Institute Center for Blood Disorders
Seattle, Washington

Alli McClanahan, MSN, APRN, ANP-BC
Nurse Practitioner
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Elizabeth Zerante, MS, AGACNP-BC
APN Inpatient Hematopoietic Cellular Therapy Service
University of Chicago Medicine
Chicago, Illinois

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by an educational grant from Bristol-Myers Squibb Company.

Thursday, April 29, 2021
5:00 PM – 6:30 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

  • Overview of the biologic rationale for, mechanisms of action of and process of producing and administering chimeric antigen receptor (CAR) T-cell therapies; similarities and differences among primary CAR-T platforms currently used in clinical practice
  • Design of and efficacy and safety in the pivotal studies of CD19-directed CAR T-cell therapy for diffuse large B-cell lymphoma, including ZUMA-1 (axicabtagene ciloleucel), JULIET (tisagenlecleucel) and TRANSCEND NHL 001 (lisocabtagene maraleucel), and for follicular lymphoma, including ZUMA-5 and TRANSCEND NHL 001; indications for this approach and practical incorporation into treatment algorithms
  • Available efficacy and safety data and key ongoing studies of CD19-directed CAR T-cell therapy for chronic lymphocytic leukemia, including ZUMA-8 (axicabtagene ciloleucel) and TRANSCEND CLL 004 (lisocabtagene maraleucel); future investigational strategies
  • Design, efficacy and safety in the pivotal study of the first BCMA (B-cell maturation antigen)-directed CAR T-cell therapy, idecabtagene vicleucel, for multiple myeloma; indication for use and practical incorporation into the treatment algorithm; future investigational strategies
  • Counseling patients and their caregivers about the incidence and management of side effects and toxicities of CAR T-cell therapies, particularly cytokine release syndrome, neurologic syndromes and persistent cytopenias; selecting patients suitable for treatment

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences among commercially available and investigational products.
  • Appraise existing and emerging efficacy data from clinical trials of approved and investigational CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
  • Evaluate the biologic basis for the investigation of CAR T-cell therapy for relapsed/refractory chronic lymphocytic leukemia, and educate patients regarding the potential clinical role of this strategy.
  • Appreciate available data documenting the activity of CAR T-cell therapy directed against B-cell maturation antigen, and apply this knowledge to identifying patients with multiple myeloma who may be appropriate for this approach as part of a clinical trial.
  • Recognize common adverse events associated with approved and investigational CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.
  • Recall ongoing research evaluating CAR T-cell-based approaches for various B-cell lymphomas, chronic lymphocytic leukemia and multiple myeloma, and counsel appropriate patients regarding the potential benefits of trial participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr AbramsonConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, bluebird bio, Bristol-Myers Squibb Company, C4 Therapeutics, Celgene Corporation, Genentech, a member of the Roche Group, Incyte Corporation, Juno Therapeutics, a Celgene Company, Kymera Therapeutics, MorphoSys; Contracted Research: Bristol-Myers Squibb Company, Seagen Inc. Dr JacobsonConsulting Agreements: AbbVie Inc, bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Kite, A Gilead Company, Lonza, Novartis, Precision BioSciences; Contracted Research: Kite, A Gilead Company, Pfizer Inc, Precision BioSciences. Dr RajeConsulting Agreements: Amgen Inc, bluebird bio, Celgene Corporation.

CONTRIBUTING NURSESMs McClanahan and Ms Zerante had no relevant conflicts of interest to disclose. The following nurse practitioner reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ms GlennieSpeakers Bureau: Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by an educational grant from Bristol-Myers Squibb Company.